BPC-157 is a peptide isolated from human gastric juice - uniquely stable in stomach acid. This is the basis for the oral form. Subcutaneous injection bypasses the gut entirely. Both are sold in Australia and both can be tested.
BPC-157 oral capsule
BPC-157 injectable
Route
Oral capsule
Subcutaneous injection
Gut stability
High - designed for GI tract
N/A
Systemic absorption
Lower (~10-30% est.)
~100% bioavailable
Primary research target
GI lining, leaky gut, IBD-like
Tendon, ligament, systemic recovery
Typical dose
500 mcg twice daily orally
250-500 mcg/day subcut
Identity (LC-MS) expected mass
~1419 Da (same molecule)
~1419 Da
HPLC purity benchmark
≥ 98%
≥ 98%
Common QC failure
Under-fill per capsule
Reconstitution mg/vial mismatch
Anonymised testing path
Submit 5+ capsules
Submit 1 sealed vial
Verdict
Choose oral for gut-targeted research, injection for systemic tendon/ligament work. The molecule is identical - what differs is delivery and absorption. Always confirm mg per capsule (oral) or mg per vial (injectable) via quantitative HPLC, because under-fill is the #1 failure mode in both formats.
Frequently asked questions
Does oral BPC-157 actually work?
Animal data shows GI-local effects without systemic absorption being required. For systemic effects (tendons, joints), injection is more reliable.
Can LabDoc test capsules?
Yes - submit at least 5 capsules so the lab can pool and measure mg/capsule accurately.
Is one form more counterfeited than the other?
Capsules carry more under-fill risk because filler can hide the absence of API. Always test a first-order batch.